Temple scientists ID new targets to treat fibrosis — a feature of many chronic diseases
(Philadelphia, PA) – When it comes to repairing injured tissue, specialized cells in the body known as fibroblasts are called into action. Fibroblasts give rise to healing cells called myofibroblasts, which generally is good in the short term – but bad when myofibroblast activation gets out of hand. In new work, Lewis Katz School of Medicine at Temple University (LKSOM) researchers show how fibroblast activation and myofibroblast formation occurs, providing clues as to how to target fibrosis – which impacts several chronic diseases. Kickstarting the process are stress-induced changes in mitochondrial calcium uptake.
The report, published online October 4 in the journal Nature Communications, describes in detail the novel signaling pathway by which reduced calcium uptake in mitochondria serves as the major regulator of myofibroblast differentiation and fibrosis. When mitochondrial calcium levels drop, cellular metabolism changes and a metabolite known as α-ketoglutarate is upregulated. Increased α-ketoglutarate levels in turn alter the packaging of cellular DNA, changing gene expression for the conversion of fibroblasts into fibrosis-mediating myofibroblasts.
“When fibroblast signaling alters mitochondrial calcium uptake, many metabolic changes occur to promote anabolic pathways to support the formation of these new cells and provide new sources of energy production,” said John W. Elrod, PhD, Associate Professor in the Center for Translational Medicine at LKSOM, and senior investigator on the new study. “These changes are necessary for the new role of these cells to alter the cellular environment in an attempt to repair the injured tissue.”
While myofibroblast formation is associated with acute wound healing – think the closing of a cut on the skin – the persistence of these cells can give rise to fibrotic diseases, such as liver cirrhosis, pulmonary fibrosis and heart failure.
“Our experiments show that the accumulation of fibrotic cells results directly from mitochondrial calcium-dependent genomic reprogramming involving α-ketoglutarate, which changes the structure of chromatin, or DNA packaging – a phenomenon referred to as epigenetics and that is important in regulating gene expression,” Dr. Elrod said. This the first time that extracellular signals directly modifying mitochondrial function have been linked to alterations in the cell nucleus for the generation of myofibroblasts.
“The key finding, that a change in mitochondrial calcium uptake plays a central role in metabolic and genetic reprogramming, presents new opportunities for investigation,” explained Dr. Elrod. “We hope that the new pathways we’ve identified as essential to myofibroblast formation can be manipulated to treat fibrotic disease.”
Dr. Elrod and colleagues are continuing to investigate the role of metabolism in fibrosis and plan to carry out further genome-wide sequencing studies to better understand the changes in chromatin structure that take place to maintain myofibroblasts in diseased tissues.
Alyssa A. Lombardi, an MD, PhD student researcher in Dr. Elrod’s laboratory and first author on the new report, led the research.
Other investigators contributing to the new study include Andrew A. Gibb, Ehtesham Arif, Devin W. Kolmetzky, Dhanendra Tomar, Timothy S. Luongo, Pooja Jadiya, and Emma K. Murray at the Center for Translational Medicine, Department of Pharmacology, Lewis Katz School of Medicine at Temple University; Pawel K. Lorkiewicz and Bradford G. Hill, the Institute of Molecular Cardiology, Diabetes and Obesity Center, Department of Medicine, University of Louisville; Gyorgy Hajno?czky, the MitoCare Center for Mitochondrial Imaging Research and Diagnostics, Department of Pathology Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia; Elizabeth Murphy, Systems Biology Center, National Heart Lung and Blood Institute; Zoltan P. Arany, Daniel P. Kelly, and Kenneth B. Margulies, the Translational Research Center, Perelman School of Medicine, University of Pennsylvania.
The research was supported in part by National Institutes of Health grants R01HL136954, R01HL123966, 3R01HL123966-05S1, and R01HL142271.
About Temple Health
Temple University Health System (TUHS) is a $2.1 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS’s physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.
It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.